Rocket Pharmaceuticals sells PRV for $180 million
Rocket Pharmaceuticals closed the sale of its FDA-granted Rare Pediatric Disease Priority Review Voucher for $180 million, extending its financial runway into Q2 2028. The voucher was granted in March 2026 alongside the approval of KRESLADI™ for LAD-I. Pro forma cash, cash equivalents, and investments now total approximately $322.6 million.
*this image is generated using AI for illustrative purposes only.
Rocket Pharmaceuticals, Inc. has closed the sale of its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $180 million. The transaction strengthens the company's balance sheet, extending its financial runway into the second quarter of 2028.
The voucher was granted by the FDA in March 2026 in connection with the approval of KRESLADI™, Rocket's gene therapy for severe leukocyte adhesion deficiency-I (LAD-I), a rare and life-threatening primary immunodeficiency. Prior to the sale, the company reported cash, cash equivalents, and investments of $144.4 million as of March 31, 2026.
Following the infusion of non-dilutive capital, pro forma cash, cash equivalents, and investments now total approximately $322.6 million. Rocket Pharmaceuticals expects these funds to support operations into the second quarter of 2028.
Financial Position
| Metric | Amount |
|---|---|
| Cash position (pre-sale) | $144.4 million |
| PRV sale proceeds | $180 million |
| Pro forma cash position | $322.6 million |
| Cash runway | Q2 2028 |
Rocket Pharmaceuticals is a fully integrated biotechnology company advancing gene therapies for rare and devastating cardiovascular diseases, with additional programs in hematology and immunology.
How does Rocket Pharmaceuticals plan to allocate the $180 million in proceeds across its cardiovascular, hematology, and immunology programs?
What are the key clinical milestones expected to be achieved before the new financial runway expires in Q2 2028?
Will the company pursue additional non-dilutive funding strategies or consider future capital raises to extend operations beyond 2028?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
